1. FDA Eyes Testosterone Therapy Expansion for Libido as GLP-1 Dominance Faces Scientific Challenge
The FDA is considering expanding the approved uses of testosterone therapy to address low libido, a move that could reshape treatment options for sexual dysfunction. This regulatory shift coincides with a significant scientific challenge to the presumed dominance of GLP-1 drugs in the obesity market. Pioneering researc...